Wednesday, July 13, 2011

Doctors threaten Medicaid cutoff in Puerto Rico (AP)

SAN JUAN, Puerto Rico � Physicians are threatening to stop serving nearly a million Puerto Ricans as a result of a dispute between the island's government and an insurance company over reimbursements for treating poor people.

Gov. Luis Fortuno on Wednesday appealed to the doctors to avoid cutting off patients, saying it would be illegal. In an interview with WAPA, a local TV station, he also said the government would withhold two months of payments to the insurance company unless it settled with doctors, hospitals, laboratories and others.

Just hours after Fortuno spoke, the island's health secretary announced the government paid $57 million of the $87 million it owed Medical Card System Inc. for June. Secretary Lorenzo Gonzalez initially said the remainder would be paid only when MCS settled its bills with medical providers, but he later said it would be paid in upcoming days.

"The money is and has always been available," he said. "Our concern has been to address the complaints of providers."

Physicians say MCS owes them as much as $60 million. They plan to decide soon if they will stop stop seeing Medicaid patients until they get paid, said Dr. Joaquin Vargas, president of the Independent Practice Association, which represents 38 medical groups.

"If this payment does not occur, the services will be threatened," he said. "It is a painful situation for us."

MCS president Jose Duran said in a statement that the company will start paying providers starting Friday, but he did not specify how much of the pending debt would be paid.

The standoff began shortly after the government launched a revamped Medicaid program in October, promising patients extended hours, more access to mental health services and fewer pre-approvals required to see specialists. The program caters to those who make less than $800 a month and to the disabled.

But complaints about delayed payments began to surface in December and have increased in recent months. As a result, the government announced last week it was terminating an $810 million contract with MCS, the largest insurance provider under the revamped program.

Hospitals claim MSC owes them $91 million and pharmacies say it owes them $6 million, said Frank Diaz-Gines, executive director of the territorial Health Insurance Administration.

MCS blames the government, saying it is owed nearly $243 million for services it has provided.

The government said it owes MCS only $87.5 million for services provided before June, and most of that was for services unrelated to the new Medicaid program.

Diaz-Gines said the government will pay its $15.3 million government debt to MCS for the Medicaid program once MCS improves its services.

No problems have been reported with two other smaller health insurance companies that also provide services under the new Medicaid program.

As the standoff continues, legislators are debating a proposal to make the Health Insurance Administration or another government agency the sole payer to medical providers, eliminating involvement by insurance companies.

"We wanted to do something different after seeing that health insurance companies were having trouble," said Sen. Margarita Nolasco, the bill's co-author. "The doctors were complaining, the hospitals were complaining, the laboratories were complaining."

The Senate has approved the bill, which is now being debated by the House of Representatives.

Nolasco said eliminating the role of health insurance companies might be the solution.

"They are a business, and that is legitimate," she said. "But it cannot be done at the cost of people's health."

Fortuno, however, told reporters late Wednesday that he did not support the bill. He said the U.S. government, which provides 30 percent of the program's budget, would not allow such a change.



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

Pills prevent HIV in straight men and women (AP)

ATLANTA � Two new studies found that daily pills prevented infection with the AIDS virus in heterosexual men and women in Africa, bringing new hope for someday offering a medical shield against HIV infection.

"This is good news. This is a good day for HIV prevention," said Dr. Lynn Paxton of the U.S. Centers for Disease Control and Prevention, who has coordinated the agency's research into HIV prevention.

Earlier this year, another study found the same pills did not prevent the AIDS virus among women in Kenya, Tanzania and South Africa. But researchers now say that study may have been flawed based on the success of the two studies announced Wednesday.

The first of the new studies, run by the CDC, involved more than 1,200 men and women in Botswana. About half got a daily pill, Truvada, an HIV treatment made by Gilead Sciences Inc. The other half got a fake pill.

An analysis of people who were believed to be regularly taking the pills found four of those on Truvada became infected with HIV, compared to 19 on the dummy pill. That means the real drug lowered the risk of infection by roughly 78 percent, researchers said.

The second study was funded by the Bill & Melinda Gates Foundation and run by the University of Washington. It involved more than 4,700 heterosexual couples in Kenya and Uganda. In each couple, one partner had HIV and the other did not. The uninfected were given either daily placebos, Truvada pills, or another Gilead treatment, Viread.

The study found 13 HIV infections among those on Truvada, 18 in those on Viread, and 47 of those on dummy pills. So the medications reduced the risk of HIV infection by 62 percent to 73 percent, the researchers said.

An independent review panel on Sunday said the benefit was clear-cut and stopped giving placebos, instead offering the preventive pills. Essentially, they deemed it unethical to withhold the medications from people who had been on placebo, said Dr. Jared Baeten, the University of Washington researcher who co-chaired the study.

"Our results provide clear evidence that this works in heterosexuals," he said.

In both studies, participants also were offered counseling and free condoms, which may help explain the relatively low overall infection rate.

The studies were to be announced at an AIDS conference in Rome next week. But following the recommendation of the review panel to the University of Washington study, both the CDC and the Washington team made hasty decisions to release the results.

These are the third and fourth widely reported studies of AIDS prevention medications.

The first was announced last year. It was a study of Truvada in gay men in Peru, Ecuador, Brazil, South Africa, Thailand and the United States (San Francisco and Boston). The drug lowered the chances of infection by 44 percent, and by 73 percent or more among men who took their pills most faithfully.

Experts celebrated. The CDC gave advice to doctors on prescribing Truvada along with other prevention services for gay men, based on those encouraging results.

But momentum seemed to stall in April, when an interim analysis of the study of 3,900 women in Kenya, Tanzania and South Africa did not show a benefit from taking Truvada.

Scientists are still piecing together why that study pointed to failure and the two latest indicate success. One theory is that the women in the earlier study did not take the medication as often as they should have, Paxton said.

Gilead Sciences of Foster City, Calif., is a major producer of AIDS drugs. On Tuesday, United Nations health officials announced the company had agreed to allow some of its drugs to be made by generic manufacturers, potentially increasing their availability in poor countries.



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials